AURA Stock Summary and Trading Ideas (Aura Biosciences | NASDAQ:AURA)

Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.

Aura Biosciences trades on the NASDAQ stock market under the symbol AURA.

As of January 23, 2026, AURA stock price declined to $5.68 with 152,715 million shares trading.

AURA has a beta of 1.61, meaning it tends to be more sensitive to market movements. AURA has a correlation of 0.33 to the broad based SPY ETF.

AURA has a market cap of $360.70 million. This is considered a Small Cap stock.

In the last 3 years, AURA traded as high as $13.50 and as low as $4.35.

The top ETF exchange traded funds that AURA belongs to (by Net Assets): VTI, IWM, VXF, IBB, IWN.

AURA has underperformed the market in the last year with a return of -28.4%, while the SPY ETF gained +14.9%. In the last 3 month period, AURA fell short of the market, returning -1.4%, while SPY returned +3.5%. However, in the most recent 2 weeks AURA has outperformed the stock market by returning +10.1%, while SPY returned 0.0%.

AURA support price is $5.48 and resistance is $6.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AURA shares will trade within this expected range on the day.